Company news
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) news
Every Adaptive Biotechnologies Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
July 29, 2026
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
July 9, 2026
Adaptive Biotechnologies : Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
June 30, 2026
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
June 17, 2026
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
June 15, 2026
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
June 15, 2026
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
May 29, 2026
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
May 5, 2026
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
April 15, 2026
Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
March 5, 2026
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
February 5, 2026
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
January 27, 2026
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
January 22, 2026
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 12, 2026
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
December 15, 2025
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
December 9, 2025
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ...
December 6, 2025
Future in Tech Appoints Ed Moyle as Chief Information Security Officer
December 2, 2025
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at...
November 24, 2025
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
November 5, 2025
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 27, 2025
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
August 5, 2025
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
July 15, 2025
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
July 1, 2025
Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors
June 3, 2025
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment...
May 30, 2025
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
May 1, 2025
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
April 10, 2025
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
April 8, 2025
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell...
March 11, 2025
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
January 22, 2025
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
January 14, 2025
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is...
January 7, 2025
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Im...
December 7, 2024
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at t...
December 3, 2024
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
November 7, 2024
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
November 7, 2024
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
October 9, 2024
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
August 29, 2024
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
August 1, 2024
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
July 11, 2024
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming...
May 31, 2024
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
May 7, 2024